# OnCo record crescent-biopharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/crescent-biopharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "crescent-biopharma" ;
  schema:name "Crescent Biopharma"@en ;
  schema:alternateName "Crescent Biopharma, Inc."@en ;
  schema:description "Crescent Biopharma is developing an antibody that blocks two cancer pathways at once, the PD-1 immune brake and the VEGF blood-vessel signal, alongside antibody-drug conjugates. Its lead antibody is in an international phase 1/2 trial."@en ;
  schema:url <https://onco.cc/companies/crescent-biopharma/>, <https://www.crescentbiopharma.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.crescentbiopharma.com/>, <https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm>, <https://investors.crescentbiopharma.com/news-releases/news-release-details/crescent-biopharma-announces-fda-clearance-ind-application-cr> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pdl1/> ;
  onco:trials <https://onco.cc/trials/nct07335497/> .